FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003405710> ?p ?o ?g. }

• W2003405710 endingPage "45" @default.
• W2003405710 startingPage "39" @default.
• W2003405710 abstract "Abstract Background and Aims: Failed primary anti‐ Helicobacter pylori therapy results in a high rate of antimicrobial resistance. This necessitates a search for new regimens to cure H. pylori infection. The aim of this study was to evaluate the efficacy and tolerability of a new levofloxacin‐containing 7‐day triple therapy and to compare it with that of standard French triple therapy in patients with known H. pylori susceptibility to MET (metronidazole) and CLA (clarithromycin). Patients and Methods: Sixty‐one patients with documented antibiotic sensitivity ( E ‐test) and an indication for anti‐ H. pylori treatment based on the Maastricht Consensus 2/2000 guidelines were randomized to receive either esomeprazole 2 × 40 mg, levofloxacin 2 × 500 mg, and amoxicillin 2 × 1 g for 7 days (ELA, n = 30), or esomeprazole 2 × 20 mg, clarithromycin 2 × 500 mg, and amoxicillin 2 × 1 g for 7 days (ECA, n = 31). A cure check was performed 4–6 weeks after conclusion of therapy. Results: Sixty‐one patients were randomized to the two treatment groups. Twenty‐eight of 30 patients of the ELA group were available for per‐protocol (PP) analysis, of whom 26 (92.9% CI: 76–99%; intention‐to‐treat [ITT] analysis 86.7% CI: 68–96%) became H. pylori negative compared with 26 of the 31 patients of the ECA group (83.9%, CI: 66–93% both PP and ITT analyses). Five patients of the ELA group showed CLA resistance, three of whom also showed MET resistance, and all five were treated successfully. Two patients with levofloxacin‐resistant strains, one in each group, were cured. Both regimens were generally well tolerated with minor adverse events being seen in 15 patients (51.7%) of the ELA group and in 13 (40.6%) of the ECA group. None of the patients discontinued treatment prematurely due to adverse events. Conclusion: The data of this pilot study suggest a better than 80% efficacy of the new 7‐day levofloxacin triple therapy, which is within the range of the French triple therapy in patients with MET‐ and CLA‐susceptible strains. The data suggest that the new levofloxacin triple therapy may also be an option in patients with MET‐ and CLA‐resistant H. pylori strains." @default.
• W2003405710 created "2016-06-24" @default.
• W2003405710 creator A5020371593 @default.
• W2003405710 creator A5045193858 @default.
• W2003405710 creator A5051921047 @default.
• W2003405710 creator A5054331215 @default.
• W2003405710 creator A5065440172 @default.
• W2003405710 creator A5071394928 @default.
• W2003405710 creator A5073620181 @default.
• W2003405710 creator A5084794271 @default.
• W2003405710 creator A5086068187 @default.
• W2003405710 creator A5089235164 @default.
• W2003405710 creator A5091851420 @default.
• W2003405710 date "2006-01-18" @default.
• W2003405710 modified "2023-10-17" @default.
• W2003405710 title "7-Day Triple Therapy of Helicobacter pylori Infection with Levofloxacin, Amoxicillin, and High-Dose Esomeprazole in Patients with Known Antimicrobial Sensitivity" @default.
• W2003405710 cites W13626767 @default.
• W2003405710 cites W1691079923 @default.
• W2003405710 cites W1829085123 @default.
• W2003405710 cites W1889281716 @default.
• W2003405710 cites W1976009314 @default.
• W2003405710 cites W1979575236 @default.
• W2003405710 cites W1984316482 @default.
• W2003405710 cites W1989955510 @default.
• W2003405710 cites W1991280309 @default.
• W2003405710 cites W1993058932 @default.
• W2003405710 cites W1995871909 @default.
• W2003405710 cites W2000180331 @default.
• W2003405710 cites W2000188193 @default.
• W2003405710 cites W2011804255 @default.
• W2003405710 cites W2024692727 @default.
• W2003405710 cites W2030304316 @default.
• W2003405710 cites W2038248809 @default.
• W2003405710 cites W2040663826 @default.
• W2003405710 cites W2042913461 @default.
• W2003405710 cites W2043686966 @default.
• W2003405710 cites W2052231020 @default.
• W2003405710 cites W2057863812 @default.
• W2003405710 cites W2061938579 @default.
• W2003405710 cites W2063485240 @default.
• W2003405710 cites W2067126845 @default.
• W2003405710 cites W2069631638 @default.
• W2003405710 cites W2081721924 @default.
• W2003405710 cites W2101950652 @default.
• W2003405710 cites W2106683700 @default.
• W2003405710 cites W2108309284 @default.
• W2003405710 cites W2112025021 @default.
• W2003405710 cites W2121961138 @default.
• W2003405710 cites W2123848597 @default.
• W2003405710 cites W2141018096 @default.
• W2003405710 cites W2151678454 @default.
• W2003405710 cites W2155637762 @default.
• W2003405710 cites W2159156126 @default.
• W2003405710 cites W2164497230 @default.
• W2003405710 cites W2166670508 @default.
• W2003405710 cites W2948387191 @default.
• W2003405710 cites W4242028510 @default.
• W2003405710 doi "https://doi.org/10.1111/j.0083-8703.2006.00375.x" @default.
• W2003405710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16423088" @default.
• W2003405710 hasPublicationYear "2006" @default.
• W2003405710 type Work @default.
• W2003405710 sameAs 2003405710 @default.
• W2003405710 citedByCount "74" @default.
• W2003405710 countsByYear W20034057102012 @default.
• W2003405710 countsByYear W20034057102013 @default.
• W2003405710 countsByYear W20034057102014 @default.
• W2003405710 countsByYear W20034057102015 @default.
• W2003405710 countsByYear W20034057102016 @default.
• W2003405710 countsByYear W20034057102017 @default.
• W2003405710 countsByYear W20034057102018 @default.
• W2003405710 countsByYear W20034057102020 @default.
• W2003405710 countsByYear W20034057102021 @default.
• W2003405710 countsByYear W20034057102022 @default.
• W2003405710 countsByYear W20034057102023 @default.
• W2003405710 crossrefType "journal-article" @default.
• W2003405710 hasAuthorship W2003405710A5020371593 @default.
• W2003405710 hasAuthorship W2003405710A5045193858 @default.
• W2003405710 hasAuthorship W2003405710A5051921047 @default.
• W2003405710 hasAuthorship W2003405710A5054331215 @default.
• W2003405710 hasAuthorship W2003405710A5065440172 @default.
• W2003405710 hasAuthorship W2003405710A5071394928 @default.
• W2003405710 hasAuthorship W2003405710A5073620181 @default.
• W2003405710 hasAuthorship W2003405710A5084794271 @default.
• W2003405710 hasAuthorship W2003405710A5086068187 @default.
• W2003405710 hasAuthorship W2003405710A5089235164 @default.
• W2003405710 hasAuthorship W2003405710A5091851420 @default.
• W2003405710 hasConcept C126322002 @default.
• W2003405710 hasConcept C168563851 @default.
• W2003405710 hasConcept C197934379 @default.
• W2003405710 hasConcept C2776409635 @default.
• W2003405710 hasConcept C2776962512 @default.
• W2003405710 hasConcept C2777396551 @default.
• W2003405710 hasConcept C2778204628 @default.
• W2003405710 hasConcept C2778375690 @default.
• W2003405710 hasConcept C2779708577 @default.
• W2003405710 hasConcept C2781276175 @default.
• W2003405710 hasConcept C501593827 @default.
• W2003405710 hasConcept C71924100 @default.

• next